MX2016001978A - Forma 2 polimorfa cristalina de una sal de n-[1-6-(etinil-3-oxo-he xahidro-furo [3,2-b] pirrolo-4-carbonil)-3-metil-butil]-4-[5-fluor o-2-(4-metil-piperazinil) tiazol-4-il]-benzamida util como inhibidor de proteasa cisteina. - Google Patents

Forma 2 polimorfa cristalina de una sal de n-[1-6-(etinil-3-oxo-he xahidro-furo [3,2-b] pirrolo-4-carbonil)-3-metil-butil]-4-[5-fluor o-2-(4-metil-piperazinil) tiazol-4-il]-benzamida util como inhibidor de proteasa cisteina.

Info

Publication number
MX2016001978A
MX2016001978A MX2016001978A MX2016001978A MX2016001978A MX 2016001978 A MX2016001978 A MX 2016001978A MX 2016001978 A MX2016001978 A MX 2016001978A MX 2016001978 A MX2016001978 A MX 2016001978A MX 2016001978 A MX2016001978 A MX 2016001978A
Authority
MX
Mexico
Prior art keywords
methyl
furo
thiazol
ethynyl
pyrrole
Prior art date
Application number
MX2016001978A
Other languages
English (en)
Other versions
MX369144B (es
Inventor
Grabowska Urszula
SALVADORE-ODEN Lourdes
M Diaz Perez Victor
Carr Andrew
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of MX2016001978A publication Critical patent/MX2016001978A/es
Publication of MX369144B publication Critical patent/MX369144B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se proporciona una forma 2 cristalina polimorfa que consiste de monoclorhidrato de N-[1-6-(etinil-3-oxo-hexahidro-furo[3,2-b]pirro lo-4-carbonil)-3-metil-butil]-4-[5-fluoro-2-(4-metil-piperazin-1- iI)tiazol-4-iI]-enzamida y monoclorhidrato hidrato de N-[1-6-(etinil-3-oxo-hexahidro-furo[3,2-b]pirrolo-4-carbonil)-3-m etil-butil]-4-[5-fluoro-2-(4-metil-piperazin-1-iI)tiazol-4-iI]-be nzamida, su uso como un medicamento y métodos para su preparación.
MX2016001978A 2013-08-13 2014-08-13 Forma 2 polimorfa cristalina de una sal de n-[1-6-(etinil-3-oxo-he xahidro-furo [3,2-b] pirrolo-4-carbonil)-3-metil-butil]-4-[5-fluor o-2-(4-metil-piperazinil) tiazol-4-il]-benzamida util como inhibidor de proteasa cisteina. MX369144B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1314503.2A GB201314503D0 (en) 2013-08-13 2013-08-13 Cysteine protease inhibitor salt
PCT/EP2014/067374 WO2015022385A1 (en) 2013-08-13 2014-08-13 Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor

Publications (2)

Publication Number Publication Date
MX2016001978A true MX2016001978A (es) 2017-01-26
MX369144B MX369144B (es) 2019-10-30

Family

ID=49262126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001978A MX369144B (es) 2013-08-13 2014-08-13 Forma 2 polimorfa cristalina de una sal de n-[1-6-(etinil-3-oxo-he xahidro-furo [3,2-b] pirrolo-4-carbonil)-3-metil-butil]-4-[5-fluor o-2-(4-metil-piperazinil) tiazol-4-il]-benzamida util como inhibidor de proteasa cisteina.

Country Status (17)

Country Link
US (1) US9650388B2 (es)
EP (1) EP3033345B1 (es)
JP (1) JP6530752B2 (es)
KR (1) KR102271944B1 (es)
CN (1) CN105612160B (es)
AU (1) AU2014307850B8 (es)
BR (1) BR112016003169B1 (es)
CA (1) CA2920797C (es)
EA (1) EA032409B1 (es)
GB (1) GB201314503D0 (es)
HK (1) HK1218915A1 (es)
MX (1) MX369144B (es)
MY (1) MY180170A (es)
SG (1) SG11201600979SA (es)
TW (1) TWI648278B (es)
WO (1) WO2015022385A1 (es)
ZA (1) ZA201600952B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0817425D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
GB0817424D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
CN102858751A (zh) * 2009-12-10 2013-01-02 美迪维尔英国有限公司 半胱氨酸蛋白酶抑制剂

Also Published As

Publication number Publication date
EP3033345A1 (en) 2016-06-22
KR20160042107A (ko) 2016-04-18
AU2014307850A1 (en) 2016-03-03
EP3033345B1 (en) 2017-07-26
JP6530752B2 (ja) 2019-06-12
MX369144B (es) 2019-10-30
CA2920797C (en) 2021-06-15
JP2016530260A (ja) 2016-09-29
HK1218915A1 (zh) 2017-03-17
KR102271944B1 (ko) 2021-07-02
BR112016003169A2 (es) 2017-08-01
CN105612160A (zh) 2016-05-25
CA2920797A1 (en) 2015-02-19
BR112016003169B1 (pt) 2023-02-23
SG11201600979SA (en) 2016-03-30
WO2015022385A1 (en) 2015-02-19
US20160194334A1 (en) 2016-07-07
TW201536788A (zh) 2015-10-01
CN105612160B (zh) 2017-11-24
AU2014307850A8 (en) 2017-03-02
EA032409B1 (ru) 2019-05-31
MY180170A (en) 2020-11-24
AU2014307850B2 (en) 2017-02-02
TWI648278B (zh) 2019-01-21
GB201314503D0 (en) 2013-09-25
EA201690373A1 (ru) 2016-07-29
AU2014307850B8 (en) 2017-03-02
US9650388B2 (en) 2017-05-16
ZA201600952B (en) 2017-07-26

Similar Documents

Publication Publication Date Title
PH12020500485A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PH12020550034A1 (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
MY180083A (en) Tetrahydropyrrolothiazine compounds
AU2014267235A8 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
PH12016502398A1 (en) Dihydropyrimido loop derivative as hbv inhibitor
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MY161757A (en) Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
PH12015501649A1 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
MY170656A (en) Kinase inhibitors
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
SG11201900868XA (en) Ido1 inhibitor and preparation method and application thereof
NZ703714A (en) 2-aminopyrazine derivatives as csf-1 r kinase inhibitors
MA39866A (fr) Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle
MY172422A (en) Pyrazole compound and pharmaceutical use thereof
MX2015017156A (es) Inhibidores de bace.
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
MX2019007629A (es) Proceso para la preparacion de un derivado de 2-piridiletilcarboxamida.
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
SG11202003225YA (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
MY193239A (en) Novel b-lactamase inhibitors
IN2015DN03235A (es)
MX2016001978A (es) Forma 2 polimorfa cristalina de una sal de n-[1-6-(etinil-3-oxo-he xahidro-furo [3,2-b] pirrolo-4-carbonil)-3-metil-butil]-4-[5-fluor o-2-(4-metil-piperazinil) tiazol-4-il]-benzamida util como inhibidor de proteasa cisteina.
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative

Legal Events

Date Code Title Description
FG Grant or registration